Safety profile of ajmaline testing in Brugada syndrome: influence of SCNA5 mutations

12 April 2026 (08:00 - 15:30)

Organised by:

Sign in for access options

Sign in to view the resources

Sign in for access options

About the speaker

Professor Vincent Probst

University Hospital of Nantes, Nantes (France)

5 More presentations in this session

Presentation thumbnail

Electrocardiographic imaging of repolarisation abnormalities in structural heart disease for characterisation of arrhythmogenic phenotypes

Doctor J. Tonko (London, GB)

Abstract Slides

Presentation thumbnail

Volumetric source imaging for the non-invasive localization of septal ventricular tachycardia circuits

Mrs J. Reventos-Presmanes (Barcelona, ES)

Abstract Slides Video

Presentation thumbnail

Guiding the e-field for advanced transmural mapping with novel modification to perpendicular electrode arrangement: advent of a new diagnostic catheter

Mr S. Masse (Toronto, CA)

Abstract Slides Video

Presentation thumbnail

First clinical experience with ECG-based non-invasive 3D mapping in patients with ventricular arrhythmias

Doctor D. Dischl (Munich, DE)

Abstract Slides Video

Presentation thumbnail

Electrocardiographic imaging (ECGi) guiding idiopathic ventricular tachycardia ablation

Doctor J. Cravo (Lisbon, PT)

Abstract Slides Video

Access the full session

Session thumbnail

Diagnostic methods in ventricular arrhythmias (2)

The Event

Event poster

EHRA 2026

12 April - 14 April 2026

You may be interested in

Congress Presentation

Prognosis of Brugada patients according to their SCN5A genetic status.

Congress Presentation

Association between genetic variants and electrocardiographic phenotype in Brugada syndrome

Congress Presentation

Beyond brugada syndrome: a new SCN5A frameshift mutation unveiling severe conduction system disease

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources